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ABSTRACT 
 
Background: Long-term survivorship in pediatric and young patients has vastly improved over the 
years, leading to research looking beyond acute treatment risks. Post-treatment quality of life 
assessments have found a gap in the fertility needs of these individuals. Aside from the physical 
issues surrounding fertility assistance prior to cancer therapy, a number of other issues arise such 
as psychological factors, social concerns, and ethical considerations that warrant a discussion all on 
their own. 
 
Objective: Barriers to reproductive medicine when presented with a cancer diagnosis come from a 
lack of basic science, translational, and clinical research. It is the duty of the oncologist to familiarize 
themselves with options in fertility preservation. This thesis hopes to consolidate pieces of 
convincing data and provide an analysis of the options to diffuse some of the uncertainty 
surrounding these discussions. Additionally, suggestions will be made, where applicable, for 
supplemental research to bridge gaps in current knowledge. 
 
Findings: Several options are available, with significant caveats and limitations. With few 
established techniques and more that are under investigation, not many can be confidently and 
fairly promoted to all cancer patients. Often, logistics of timing and personnel coordination get in the 
way of utilizing this technology. Even so, there is a lack of open dialogue between the treating 
physician and cancer patients of childbearing age regarding the field of oncofertility. 
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Conclusion: There is a need to protect the autonomy and vulnerability of each patient who is 
diagnosed with any form of cancer. The field of oncofertility should aim to serve all young cancer 
survivors with the opportunity to protect their fertility and long-term quality of life. In order to do so, 
healthcare providers from across different fields must work together to coordinate a patient’s best 
interest; only with constant communication and discussion between various disciplines will cancer 
patients receive the most appropriate information for their situation.   
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INTRODUCTION 
 As we move into an era of better diagnostics and therapeutics, the burden of 
cancer on patients under the age of 40 becomes an issue that needs careful consideration. 
Advancements in treatments of childhood cancer have improved dramatically over the 
past few decades and as a result, the number of cancer-related deaths in pediatric and 
young adult patients has steadily declined. Now, nearly 80% of young cancer patients 
survive the harsh treatments and go on to lead a normal life (Revel and Revel-Vilk, 
2010). Most evident in breast cancer, over the past few years there has been a notable 
increase in disease-free survival rates with a simultaneous decline in mortality (Noyes et 
al., 2010). However, despite such victories, many effective treatments that result in 
overall survival are cytotoxic, specifically for the reproductive organs, and may 
compromise a young patient’s fertility. In females, premature ovarian failure is a major 
corollary. Bridging the gap between surviving cancer and reproductive challenges, tissue 
cryopreservation techniques offer a promising improvement to a young cancer survivor’s 
quality of life. 
 The literature discusses a number of ways in which fertility can be preserved 
safely and effectively. The options differ slightly between females and males, with more 
established methods for males, but more experimental techniques for women. 
Historically, men have had the option and ability to preserve genetic material, while the 
options for women have been limited.  Fertility options for males currently include sperm 
cryopreservation (sperm banking), which is quite effective, or use of donor sperm with 
  
 
 
 
 
2 
 
testicular tissue preservation (still under experimental testing), but no techniques are 
currently available for pre-pubescent boys (Anderson and Wallace, 2011). When options  
arose for women, embryo cryopreservation became the go-to thanks to research in in 
vitro fertilization. For women, more techniques have been established since the beginning 
stages of fertility preservation. While more established means of having a baby, such as 
in vitro or adoption, are worth exploring, success has been seen with cryopreservation 
techniques at different stages of ovarian maturation (Donnez et al., 2011). As can be seen 
in Figure 1, there are a number of options that should be considered and communicated to 
the patient depending on certain factors such as cancer type, stage, and the individual’s 
Figure 1: A) Fertility Preservation Options Before Treatment, B) Fertility Preservation 
Options After Treatment (Donnez et al., 2011) 
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age, before they undergo treatment. Once treatment has already begun, fertility options 
and the window for assisted reproduction narrows significantly (Donnez et al., 2011).  
For this reason, this paper will focus more on female fertility preservation options, 
while simply touching on the limited possibilities for men. Techniques ranging from 
oocyte cryopreservation, embryo cryopreservation, complete ovarian tissue harvesting, 
and gonadal shielding are all moving quickly into the forefront of oncofertility research 
(Kim and Jeon, 2012). Transplantation of frozen-thawed tissue has proven successful and 
resulted in a number of healthy births since 2004 (Donnez et al., 2011). However, there 
are many risks associated with this procedure. The most important factors to consider 
before undergoing fertility treatments are age and type of cancer treatment (Schmidt et 
al., 2010). Currently, the female procedures require about a 3-week delay in starting 
chemotherapy to allow for ovulation and follicular growth. This delay may not be a 
feasible option for some fast growing malignancies (Revel and Revel-Vilk, 2010). 
 Additionally, there is a movement to improve referral methods with young 
women diagnosed with cancer. By creating a stronger link between the fields of oncology 
and reproductive health, the quality of life for many cancer survivors can be greatly 
improved (Lee et al., 2010). The potential impact of these techniques could be profound 
but research must first address some key questions, for instance, would the reimplanted 
tissue function the same way and is there risk of recurrent cancer from the tissue (Kolp 
and Hubayter, 2011)? Additional ethical considerations suggest that the field of 
oncofertility is still in its youth with more research to be done ranging from bench to 
bedside and everyplace in between. 
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OBJECTIVES 
 Just a few decades ago, most of the patients with malignant disease under the age 
of 15 died from either lack of a treatment or the therapy itself. Now, the 5-year survival 
rate of all childhood cancers is close to 70-75%. Figure 2 depicts clearly improved, 
statistically significant survival rates for three cancers often affecting individuals of 
childbearing age: leukemia, Hodgkin lymphoma, and non-Hodgkin lymphoma. With 
more and more cancer survivors, the focus in research has shifted to include ways of 
improving the quality of life of these individuals.  
 There is a consensus that more information is needed in order to further this 
interdisciplinary field. There must be extreme caution in delaying chemotherapeutic 
treatments and as always, there are risks with re-implantation. The main concerns are 
about efficacy and possible reoccurrence of cancer. While the general view of 
oncofertility is that it is an up-and-coming, rapidly growing field, efforts to push research 
Figure 2: Survival rates from 1975-2006 for three cancer types (Smitz et al., 2009) 
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forward is held back by the lack of donor tissues, funding, and understanding of the basic 
science behind it. Additionally, animal models usually provide significant insight into 
human workings and can be a stepping stone for translational research, but with 
reproductive differences that vary greatly, this process becomes much more difficult 
(Smitz et al., 2009).  
 This thesis aims to identify the benefits and risks associated with cryopreservation 
techniques. The effect of chemotherapeutics on reproductive tissues, the procedures 
involved in preserving fertility cryogenically, as well as the current successes is an 
ongoing study. I hope to uncover the steps that need to be taken in translating research 
from bench to bedside in a timely fashion and determine questions that must be answered 
before fully implementing these technologies. I want to learn more about the ways in 
which undergoing chemotherapy can be detrimental to a young patient’s fertility and will 
help determine next steps in preserving that ability. While understandably, survival 
should be the primary focus and outcome in each cancer patient, the loss of reproductive 
ability severely impacts one’s life. This thesis will allow me to look into the various new 
technologies that may allow individuals to lead a healthy and normal reproductive life 
after remission. 
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 RESEARCH AND PERSPECTIVES 
 
Cancer Therapies and the Reproductive Axis 
 Current cancer treatments include surgery, chemotherapy, and radiation, tailored 
to each diagnosis. The most common childhood cancers are leukemias, central nervous 
system malignancies, lymphomas, soft-tissue sarcomas, renal and bone cancer (Dillon, et 
al., 2012). The number of individuals affected by various types of cancer can only expand 
as patients age. Various combinations of these cancer treatments are given depending on 
factors such as age and sex of the patient, type of cancer, extent of the cancer, and its 
location (Muller, 2003). Certainly, the risks and rewards are unique to the individual; 
because there is no specific molecular pathway that is altered for cancer and each type of 
malignancy could arguably be its own disease, overarching strategies to treat have non-
intended effects.  
 Often treatments involve any combination of irradiation, chemotherapy, radical 
surgeries and/or bone marrow transplants. Each treatment type confers different degrees 
of damage to different body systems, but they can all impact the reproductive organs or 
the hypothalamic-pituitary-gonadal axis, which ultimately can lead to reproductive 
consequences and even failure (Muller, 2003). A successful biological pregnancy relies 
on the ability of multiple organ systems to support a growing fetus as well as their ability 
to respond and adapt to a changing environment. Furthermore, because reproductive 
functioning differs greatly between sexes, pinpointing the exact sensitivities of each is 
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imperative in finding a specific plan for patients undergoing any of these altering cancer 
treatments.  
 Females are born with all of the follicles they will ever have. It has been estimated 
that during development, an embryo may have as many as 7 million germ cells (Wallace 
et al., 2003). At birth, anywhere from 1 to 2 million remain and from birth until puberty, 
over half of these follicles will already be lost to atresia (Levine, 2012). By the onset of 
puberty, only about 500,000 follicles remain; by 37 years of age, the pool decreases to 
about 25,000 (Duncan et al., 
2011). This fixed pool of 
follicles declines at a 
biexponential rate until 
menopause (Wallace, 2005). 
During menarche, the 
remaining follicles are 
stimulated by the 
hypothalamic-pituitary axis to 
mature and undergo ovulation 
(Levine, 2012). A normal 
menstrual cycle is shown in 
Figure 3, where a hormone 
from the hypothalamus, 
gonadotropin-releasing 
Figure 3: A normal menstrual cycle and maturation  
process (Levine, 2012). 
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hormone, stimulates the anterior pituitary to secrete follicle-stimulating hormone (FSH) 
and luteinizing hormone (LH). This balance of hormones, in turn stimulates follicle 
maturation and selection of a dominant follicle for release from the ovaries. The rest of 
the follicles undergo atresia and without fertilization, the dominant follicle is also lost 
through menstruation. Cancer therapies can rapidly accelerate the loss of follicles and 
leave only a short window for reproductive success. Depending on where a girl or woman 
is in reproductive age upon beginning her cancer treatment, the effects can be irreversible 
(Levine, 2012).  
 Male testes are the source of spermatogenesis and steroidogenesis (Dillon, 2012). 
The testes house a number of different cell types including Sertoli cells that produce 
endocrine substances to support germ cell growth, the germ cells themselves that 
generate sperm, and surrounding Leydig cells that produce testosterone. Though these 
cells contribute to more than fertility, male patients tend to experience infertility issues 
due to the sensitive and fast growing nature of the spermatogonia (Dillon, 2012). 
However, the potential of cancer treatments to have negative effects on pubertal 
development, sexual function, and hormonal balance should be concerning.  
 
Assessment of Reproductive Potential 
 A few markers of reproductive capacity have been used to determine a woman’s 
fertility. By definition, in order to be fertile, a woman must have normal functioning 
systems to support a pregnancy: the neuroendocrine system that can regulate ovulation 
and menstruation, a healthy ovarian follicle reserve (both in quantity and quality), a 
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uterus that will support a growing fetus, and adaptable systems such as the heart and 
kidneys to support changes like a 
large blood volume (Duncan et al., 
2011). Before cancer treatments 
begin, being able to measure the 
ovarian reserve and/or 
reproductive functioning could 
help the oncologist determine what 
the best course of cancer therapy 
will be and also help the fertility 
specialist determine whether the 
patient should consider a 
cryopreservation option. 
 The most common clinical 
tests for ovarian reserve include 
but are not limited to: hormone 
tests, ultrasound tests, and 
biological markers. First, the 
hormone tests look primarily at 
anti-mullerian hormone (AMH) or 
also known as mullerian inhibitory 
substance (MIS), and can also 
Figure 4: Changes in markers of ovarian reserve.  
A) AMH/MIS, B) FSH, C) Estradiol (Yu et al., 2010)  
 
A 
B 
C 
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consider estradiol, FSH, and inhibin B levels on the third day of menstruation. Of these 
hormones, AMH is considered the best indicator of ovarian age along with an antral 
follicle count. AMH has been noted to drop after the age of 37 and before the onset of 
menopause. This is due to the fact that AMH is produced by the granulosa cells of the 
ovaries and have a direct correlation to the number of follicles. Thus, it is thought to be 
an indicator of premature ovarian failure, but is not yet sensitive enough. Additionally, 
AMH is not affected by other factors such as contraceptive use or pregnancy and is not 
cyclical, so would not vary day-to-day. As noted, AMH is analyzed in conjunction with 
antral follicle count, which typically varies inversely. Antral follicles can be measured 
and counted on an ultrasound to estimate the number of remaining primordial follicles. 
Together, these two markers can give the fertility specialist a clearer understanding of 
primordial follicle count and remaining ovarian reserve (Duncan et al., 2011). 
  As shown in Figure 4, there is a significant drop in the levels of AMH in breast 
cancer patients with age-matched controls that can be attributed to the start of 
chemotherapy. Within a few weeks of chemotherapy, AMH levels decline to 
undetectable levels. When compared to FSH and estradiol, which return to normal levels 
in the same time frame, AMH levels remain low. Furthermore, it seemed that many 
women even resumed menstruation, despite low AMH levels. In those younger than 35 
years of age, approximately 25% did not regain menstruation and in those older than 35 
years old, roughly 50% were also amenorrheic (Yu et al., 2010). Thus, AMH has been 
suggested as the only detectable biomarker post-cancer therapy and accurate 
mathematical models or sensitive assays may be options for the future of oncofertility 
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diagnostics (Duncan et al., 2011). However, there was no relationship found between 
baseline or change in AMH levels and future menstrual function, indicating that it cannot 
be used as a predictive marker of amenorrhea. AMH levels may be more indicative of 
ovarian reserve, which seemingly recovers independently of endocrine function, and 
should remain a useful guide for ovarian reserve alone until clearer correlations can be 
drawn in further studies (Yu et al., 2010). 
 The other hormones mentioned, estradiol, FSH, and inhibin B must be measured 
on the third day of menstruation, and are typically measured in combination. Estradiol 
and FSH can be indicative of a problem with ovulation, as they are usually seen inverse 
to one another. High estradiol levels are able to suppress FSH and therefore suppress 
normal ovulation patterns (Duncan et al., 2011). Analysis of normal hormone levels 
before and after cancer therapies can be an important tool in determining the root of an 
infertility issue. 
 The other available methods are generally less reliable and inconclusive; use of 
these tests would be in conjunction with AMH and antral follicle counts. Ultrasounds can 
be used to estimate ovarian and uterine sizes to further supplement the information 
presented. The return of menstruation could indicate restoration of fertility, but not 
necessarily (Duncan et al., 2011). True fertility can vary even with these measurements, 
compelling researchers to make more sensitive assays.  
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Ovarian Failure 
 Ovarian failure can be 
classified into two main 
types: acute ovarian failure 
(AOF) or premature 
menopause. Some have 
defined ovarian failure or 
menopause as individuals 
with <1,000 follicles 
remaining. Patients who 
undergo some form of cancer 
treatment with a resulting loss 
of ovarian function are said to 
have acute ovarian failure; 
those who begin menopause 
before the age of 40 are 
considered to have premature menopause. There seems to be a direct correlation between 
age at treatment and rate of developing ovarian failure. It follows that the number of 
primordial ovarian follicles present at the onset of treatment helps determine how quickly 
ovarian failure is likely to occur (Wallace et al., 2005). Figure 5 shows how quickly the 
number of follicles can decline with the onset of chemotherapy, leaving a very narrow 
window, if any, for fertility preservation post-treatment. While the decline in the number 
Figure 5: Two possibilities of decline in follicles over time, 
accelerated by receipt of chemotherapy 
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of follicles clearly declines at a more rapid rate as compared to the natural rate, the slope 
of each can vary as well (e.g. the different effects of treatments), as seen in Figure 5a vs. 
5b. Unfortunately, physicians and researchers are unable to determine a specific model 
for any given patient and loss of follicular reserve could vary based on initial pool and 
response to treatment.  
 Studies have shown that certain cancer treatments were more likely to cause AOF 
in individuals of reproductive age. Affected survivors were more likely to be older and 
have undergone abdominal-pelvic irradiation (and it should be noted that certain types of 
cancer are more likely to be treated with this therapy) (Chemaitilly, 2010). In general, the 
effects of AOF are significant compared to their sibling counterparts, as seen in Figure 6. 
We begin to see a significant 
deviation in cancer survivors 
as compared to their siblings 
as early as age 20 when these 
individuals may become 
prematurely menopausal. A 
limitation of using premature 
ovarian failure as an 
indicator of fertility, 
however, is that it cannot be 
diagnosed until after puberty (Wallace et al., 2005).  
Figure 6: Cumulative incidence curves of premature ovarian 
failure in survivors vs. siblings (Green, Sklar et al. 2009) 
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Chemotherapeutic Toxicity  
 In order to be effective, chemotherapies must in some way inhibit cellular 
proliferation. Treatments commonly target rapidly dividing cells in the body by impeding 
various cycles of cell division (Levine, 2012). Rapidly dividing cells of the body include 
the bone marrow, gastrointestinal tract, and skin, resulting in many of the common side 
effects known with chemotherapy such as hair loss and nausea. Other chemotherapeutics 
are alkylating agents that directly disrupt and nick DNA. Yet another class is intercalating 
agents that can introduce DNA structural abnormalities by wedging themselves in 
between base pairs of DNA. These mechanisms are very effective in ridding the body of 
cancerous cells, but also impact other numerous other cell types in the body.  
 Relevant to female reproduction are the oocytes and somatic cells of the ovaries 
that are essential for a healthy reproductive cycle. The oocyte itself undergoes many 
cycles of growth and proliferation, while the somatic cells that provide support are 
replenished at a comparable rate. The quickly regenerating cells are targeted by the non-
specific cancer therapies resulting in gonadal toxicity that thus explains the amenorrhea 
of post-pubertal women 
during and following 
treatment (Levine, 2012). 
While some of the 
chemotherapeutic toxicity 
directly impacts the ovarian 
follicle numbers by 
Table 1: Some of the highly used chemotherapeutics classified 
by risk 
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damaging and triggering molecular mechanisms leading to cell death, it has been 
suggested that much of the push to acute ovarian failure can also be attributed to the 
increased rate of growth to replace damaged cells as more and more oocytes are damaged 
by drugs (Morgan et al., 2012).  
 Within current chemotherapies, researchers have classified some drugs as high 
risk (e.g. cyclophosphomide, chlorambucil, etc.), intermediate risk (e.g. cisplatin and 
adriamycin/doxorubicin), and low risk (e.g. methotrexate, 5-fluorouracil, etc.) based on 
the degree of gonadal damage. Most of these drugs fall under the category of alkylating 
agents, which, in particular, confer a higher degree of gonadotoxicity (Lee et al., 2010).  
 Alkylating agents are not cell-cycle specific and their impact on premature 
oocytes is in general, less understood. Rather than halting cell division and targeting 
rapidly dividing cells, they act by cross-linking and introducing single- or double-
stranded breaks into DNA. This mechanism of action allows these chemotherapeutics to 
act indiscriminately on quiescent and dividing gonadal cells. Examples of these agents 
include cyclophosphamide 
and procarbazine, seen in the 
high-risk category (Lee et al., 
2010). Post-therapy findings 
differ among patients, but 
often show a measurable 
decline in the number of 
follicles as well as stromal 
Figure 7: Vascular density vs. dose of doxorubicin (Solemani 
et al., 2011). 
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fibrosis (Dillon, 2012). 
Anthracyclines, such as 
adriamycin/doxorubicin and 
cisplatin, are intercalating 
agents and tend to confer a 
lower risk of gonadotoxicity 
but still damage the cell 
through microvascular and 
stromal damage (Levine, 
2012). Figure 7 shows that when ovarian tissue was treated with doxorubicin, there was 
an observed decline in vascular density within 72 hours as compared with the control 
tissues, which proliferated and showed an increase in microvasculature. Interestingly, this 
change is not seen within 24 hours, but takes effect later.  Additionally, doxorubicin 
specifically was shown to induce a molecular pathway leading to apoptosis of oocytes. 
Figure 8 shows the significant increase in proportion of dying follicles, which would 
ultimately affect ovarian function and therefore fertility potential both pre- and post-
menopausally (Soleimani et al., 2011).  
Typical therapy for Hodgkin lymphoma involves a combination of 
mechlorethamine, vincristine, procarbazine, and prednisone (MOPP therapy) with 
demonstrated ovarian failure in 39-46% of individuals. This along with other treatment 
lines that contain alkylating agents like COPP/ABVD (cyclophosphamide, vincristine, 
procarbazine, prednisone/doxorubicin, bleomycin, vinblastine, dacarbazine) and 
Figure 8. Induction of apoptosis in primordial follicles 
in a culture with doxorubicin (Solemani et al. 2011).  
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BEACOPP 
(bleomycin/etoposide/adriamycin/cyclophosphamide/oncovin/procarbazine/prednisone) 
have all been shown to result in amenorrhea and premature ovarian failure, especially in 
young adults (Levine, 2012). Doxorubicin is a key agent in these and other treatment 
courses for cancers such as breast, ovarian, endometrial, lymphomas, and leukemias, 
where the age of onset is often during childbearing age (Solemani et al., 2011). 
COPP/ABVD therapy alone resulted in ovarian failure in up to 77% of patients. It should 
be noted that ABVD has limited use of alkylating agents as compared to BEACOPP and 
thus, also less gonadotoxicity than should be expected for BEACOPP (Levine, 2012).   
 Alkylating agents and other chemotherapeutics also cause significant damage to 
male reproductive organ tissue, but current research suggests that overall impact seem 
less permanent than seen in female patients. Temporarily halted spermatogenesis has 
been seen in treatment with cisplatin-based therapies, whereas methotrexate- and 
mercaptopurine-based regimens have shown no effect on fertility (Dillon, 2012). It could 
also be suggested that DNA altering chemotherapeutics may cause mutations in sperm 
cells and may coincide with an increased risk of congenital defects and malformations, 
but research has shown no evidence of this phenomenon (Levine, 2012).  
 Ultimately, a patient’s age is the most influential factor in chemotherapy dosing 
and potential gonadotoxicity. Chemotherapeutic toxicity has a direct correlation with the 
total cumulative dose given and an inverse correlation with age at exposure (Green, Sklar 
et al., 2009). As a person ages, lower and lower doses of chemotherapeutics will result in 
ovarian decline or failure (Dillon, 2012); thus, before treatment, the oncologist must 
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consider what the best course of treatment is for the individual and their future plans. 
Combinations of drugs, length of treatment, and the total dose can have drastically 
different effects on women of the same age (Levine, 2012).  
 Certainly, within-patient deviations must contribute a great deal to the final effect 
of each regimen, but because these variations cannot be known, the ideal is to maximize 
efficacy and minimize organ damage with our current understanding of these 
chemotherapeutics. Even aside from saving reproductive capacity, preventing premature 
ovarian failure is important in normal functioning of other organ systems; associated 
comorbidities can include cardiac function, bone health, thyroid issues and more.  
 
Radiation Therapy Toxicity   
Radiation therapy can be used alone or with surgery and chemotherapy for solid 
cancers. It can be localized and target a particular area of the body, but can also directly 
involve the gonads on a few occasions: direct pelvic, abdominal, spinal, scatter, or total 
body irradiation in preparation for a bone marrow transplant (Levine, 2012). Radiation 
energy is measured in ‘grays (Gy)’, or can be described as a unit of how much radiation 
is absorbed into a certain material, in this case, various tissues (Adriaens, Smitz, and 
Jacquet, 2008). Similarly to chemotherapy, the degree of damage on the reproductive 
organs with radiation depends mainly on age, schedule of radiation, total dose of 
radiation, and number of primordial oocytes available at the time.  
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 For example, a common role of radiation therapy is seen in breast cancer 
treatment regimens, where it can be used under a few circumstances. First, radiation 
alone can be used as the primary source of treatment when the cancer is in its early stages 
and a patient prefers to preserve the breast. Radiotherapy can be used in conjunction with 
surgical removal of the growth (lumpectomy) or breast (mastectomy) with higher-risk 
patients. As stated earlier, often it is combined with other treatment methods; if 
chemotherapy is used 
first, adjuvant radiation 
therapy is an accepted 
method. Finally, in 
palliative cases or when 
breast cancer has 
metastasized, radiation 
can help in the 
management of the 
disease (Lee et al., 2010). 
With any amount of radiation, there is an increased risk of AOF, as displayed in Figure 9, 
but the impact on the ovaries seems to increase almost exponentially with increasing 
dose. 
 As female follicles are in constant decline, a mathematical model of decay allows 
predictions to be made when looking at the effects on the ovaries after treatment. It has 
been calculated that doses as low as 1-2 Gy can result in follicular depletion in younger 
Figure 9: Percentage of patients developing AOF vs. total 
dose of radiation (Green, Sklar et al. 2009) 
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girls and a dose of 4-6 Gy can negatively impact adult women. With research still 
ongoing to find a reliable biomarker for indicating ovarian failure, currently the best 
model is a mathematical decay calculated by Wallace et al. (2003). Knowledge of the 
radiosensitivity of an oocyte from basic science research allows physicians to determine a 
number of models to calculate a relatively safe range for irradiation. These estimates 
include an effective sterilizing dose of radiation that will result in premature ovarian 
failure with 95% confidence intervals, a mean sterilizing dose, and the lethal dose at 
which 50% (LD50) of the follicles or oocytes are lost (Wallace et al., 2003).  
The effective sterilizing dose has been defined as the total dose of radiation at 
which <1,000 primordial follicles will remain. The effective sterilizing dose decreases 
with age (Figure 10, red/upper); it begins around 20.3 Gy at birth and by 30 years of age, 
it is 14.3 Gy (Wallace et al., 
2005). Another measure, the 
mean sterilizing dose (Figure 
10, blue/lower), indicates the 
total dose at which 50% of 
women will suffer premature 
ovarian failure. The third 
estimate is the dose of 
radiation required to kill off 
50% of a patient’s oocytes 
(LD50), which is <2 Gy and 
Figure 10: Effective (red, upper) and Mean (blue, lower) 
Sterilizing Doses (Wallace et al. 2005) 
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lower than what has previously been reported (Wallace et al., 2003). Typical therapeutic 
regimens frequently fall well under the effective sterilizing dose; however it is still 
uncertain how much chemotherapies contribute to this premature ovarian failure alone 
and in combination with radiation therapy. Limiting the dose of radiation to the gonads is 
practiced in adults, but becomes technically difficult in children as discussed later with 
gonadal shielding (Wallace, 2005). Additionally, it is uncertain how a fractionated dosing 
schedule in radiotherapy can impact the effective and mean sterilizing doses. Thus, 
Wallace et al. (2003) have suggested that the LD50 be the upper limit of treatment due to 
the uncertainty of fractionated dosing and the potential combination of chemotherapy. 
Total body irradiation has serious impacts on multiple facets of reproduction. 
From the hypothalamic and hormonal repercussions to the physiological uterine 
dysfunctions, total body radiation results in a number of negative health outcomes. Total 
body irradiation is correlated with miscarriage, premature delivery, and low birth weight 
in women due to these effects (Wallace et al., 2005). 
 Male testicular tissue is even more sensitive to irradiation than the ovaries. A dose 
as low as 4 Gy can result in decreased spermatogenesis and negatively impact the germ 
cells, whereas a total dose of 20 Gy can cause destruction of Leydig cells and 
hypogonadism. One study has shown that up to 83% of leukemia patients receiving both 
chemotherapy and total body irradiation never regained sperm generating ability and 
became permanently sterile (Dohle, 2010). Generally, however, the male gonads can be 
well-protected and shielded from irradiation therapy with the exception of treatment 
regimes that would require total body irradiation. According to calculations of high-dose 
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cranial irradiation, 35 Gy or more could potentially cause deleterious effects of the 
hypothalamus (Levine, 2012). Conversely in one study, even cranial irradiation did not 
seem to affect the hypothalamic-pituitary-gonadal functioning in a cohort of 89 childhood 
acute lymphoblastic leukemia survivors (Dohle, 2010). A possible explanation of this 
would be that many of their total doses of radiation would still have fallen under this 
predicted value. However, this is an area where more research must be done to clearly 
identify the relationship, if any, between irradiation and endocrine functioning. Only by 
identifying the physiological mechanisms that are not working properly and suggesting 
which possible molecular pathways could be affected, can new, targeted therapies be 
researched and developed.  
 
Surgical Implications 
 Obviously, surgeries that involve removing organs necessary for reproduction 
would irreversibly impair fertility, i.e. hysterectomies (uterus) and cervical cancers 
(removal of the cervix), and can severely damage endocrine function. If detected early, in 
some cases fertility can be preserved by using more conservative techniques that retain 
the uterus so pregnancy can remain an option in the future. Even with retention and future 
conception, often these pregnancies can involve complications like higher rates of 
premature labor, miscarriage, and stillbirth (Levine, 2012).   
 Hematopoietic cell transplantation is a common treatment option for certain types 
of cancers that can be very harmful to the reproductive system. In both men and women, 
bone marrow transplants involve either or both high-dose chemotherapy and total body 
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irradiation. Whether or not the patient has undergone puberty affects the posed risk. 
Before puberty, delayed puberty and sexual development issues are of primary concern, 
while post-puberty, future fertility possibilities are at risk. In post-pubertal females the 
risk of ovarian failure was significant: researchers observed acute failure in 65-84% of 
patients that had a hematopoietic cell transplant; in pre-pubertal females, still about 57% 
of the patients had incomplete development and/or failure (Green, Sklar et al., 2009). 
Figure 11 shows the compounding effects of treatment combinations and suggests that 
the mechanisms underlying how each arm of treatment might lead to AOF are still 
unclear. Such staggering figures indicate a need for preservation techniques and beg for a 
dialogue about fertility preservation options.  
 
American Society of Clinical Oncology (ASCO) Recommendations 
Figure 11: Cumulative incidence curves of premature ovarian failure based on treatment type. A) 
Patients treated with alkylating agents. B) Patients treated with abdominal-pelvic irradiation. C) Patients 
treated with both (Green, Sklar et al. 2009). 
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 In 2006, with the growth of the field of oncofertility and the broader recognition 
of necessary improvements in quality of life for cancer survivors, ASCO published a set 
of fertility preservation options (Gracia et al., 2012). The current standards and guidelines 
from ASCO for the most well-established and accepted techniques under specific 
conditions are: embryo cryopreservation, ovarian tissue cryopreservation, gonadal 
shielding, and trachelectomies (Lee et al., 2010). As discussed later, each method has its 
advantages and drawbacks, although ASCO remains mostly conservative in its 
suggestions despite the fact that many more options are clearly unfolding in the field of 
oncofertility. Approaching this topic with patients means giving them more options to 
consider and discuss following a shocking diagnosis. ASCO’s recommendations are 
broad and should be further tailored to a subset of age groups. It is crucial for a physician 
to understand the age appropriateness of each option and remain cognizant of each 
patient’s wishes, while realizing that many patients could even be minors who have not 
given their future fertility much thought.   
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THE OPTIONS 
 
Female Fertility Preservation  
 Cancer is a progressive, often aggressive, and elusive disease that is difficult to 
treat specifically. Efforts in oncology are fixated on pinpointing the pathways gone awry 
and formulating targeted treatment options. However, because of the built-in 
redundancies of cancer cells and an ability to propagate itself via multiple pathways, 
there may not be a cure in sight for the disease. As a result, fields like oncofertility have 
cropped up to address issues that arise during and after cancer treatment. In order for 
research to transition from experimentation on animal tissue to human tissue, issues such 
as the lack of available tissue must be addressed; not only is most available human tissue 
from older women who have lost much of their reproductive potential, but they are 
generally associated with some pathology as well. An applied pressure to study human 
tissue culture in vitro would be beneficial to researchers in numerous fields, an entirely 
separate topic altogether (Smitz et al., 2009).  
 As discussed, cancer treatments can have a significant impact on the reproductive 
system depending on the age of the patient, dosing of chemotherapy and/or irradiation, 
and surgical consequences. Aside from these external forces impeding fertility 
capabilities, the cancer itself could have a high risk of ovarian metastasis, for instance, 
leukemias and lymphomas; advanced stage breast cancers can also have a moderate risk 
of metastasis to the ovaries. 
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 Thus, it should be noted that with any of these preservation options discussed 
below, established or otherwise, there is always a risk of reintroducing a malignancy 
through pre-treatment tissue. Sensitive and specific assays should and can be developed 
to test these harvested tissues for the presence of cancer cells before preservation and 
certainly before re-implantation. There have not been enough studies to confirm or deny 
the theory that contamination might occur with re-implanting tissue, but it is a real 
concern that should be closely considered and monitored in future research efforts. 
 
Gonadal Shielding 
 If radiotherapy is involved in the treatment plan, doing the best to protect the 
ovaries from extraneous harm should be a priority. Gonadal shielding utilizes external 
covers to lessen exposure. Studies have shown that individuals receiving chemotherapy 
have regained ovarian function post-treatment, but only about 10-15% of individuals 
undergoing total body irradiation have seen similar results, suggesting that its effects in 
preserving ovarian function may be overestimated (Kanda et al., 2010). In this sense, 
gonadal shielding should be part of all therapeutic regimens that involve irradiation. 
Avoiding irradiating the ovaries can have a significant effect on delaying follicular atresia 
and ovarian failure (Lee et al., 2010). One potential shortfall of gonadal shielding can 
best be illustrated with an example such as in leukemia, where gonadal shields would 
reduce the total dose of radiation, which could theoretically result in an increased 
incidence of relapse. There have not been large enough cohorts of patients in this 
situation that have been studied to determine if the threat of relapse is definite. Still, to 
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avoid this, perhaps gonadal shielding should only be practiced in patients in remission 
(Kanda et al., 2010).  
 Current designs of gonadal shields have been suggested to be unsuitable for 
younger girls as well, as the ovaries descend into the pelvic area with time and can vary 
in location by age as well as other factors like extent of bladder filling. Because the 
shields are designed to provide regional coverage, they are thus easily misplaced in 
children, conferring no degree of prevention (Fawcett et al., 2012). This option is a 
protective plan that should certainly be utilized in age-appropriate patients, but not a 
proactive method of fertility preservation post-treatment. 
 
Oophoropexy/Ovarian Transposition 
 Another option for women is oophoropexy, a surgical version of gonadal 
shielding.  In an oophoropexy, a surgeon physically transposes the ovaries so that they 
are protected somewhat from irradiation damage behind the pelvic brim or uterus. During 
total body irradiation, however, this technique is not suggested, as it does not provide any 
shielding. The best placement would be predetermined by the radiation oncologist and 
reproductive endocrinologist in order to minimize gonadal exposure (Dillon, 2012). The 
procedure can be done laparoscopically with success rates measured by recommencement 
of menstruation. Ranging anywhere from 16-90%, the success rates can vary based on the 
type of irradiation given (Chuai et al., 2012). Surgical transposition is a risky process as it 
can lead to damage of the reproductive organ systems, i.e. fallopian tube damage or 
ovarian vascular damage, if not managed well. Oophoropexy heavily relies on constant 
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communication between those individuals maintaining and optimizing the patient’s 
different interests.  
 
Embryo Cryopreservation 
 Embryo cryopreservation has been well established primarily in the field of in 
vitro fertilization and is borrowed in oncofertility to preserve reproductive capacity 
during cancer treatments. While it is the most common and successful technique in 
practice, a patient choosing to undergo this treatment must be post-pubertal, have a 
partner to donate to sperm or use donor sperm (Dillon, 2012). For this reason alone, 
embryo cryopreservation is not a realistic option for pediatric and adolescent cancer 
patients, nor is it ideal for single women, but is more appropriate for adult females with a 
committed partner. Embryo cryopreservation also requires an allotment of time for 
ovarian stimulation via injections of hormones timed to a woman’s natural menses to 
promote ovulation, followed by oocyte collection, which could potentially take up to 2-6 
weeks (Chuai et al., 2012). Many younger patients who are already on oral contraceptive 
pills may even be able to bypass this waiting period, as hormone stimulation and fertility 
treatments can begin just a few days after discontinuation of the pill (Noyes et al., 2010).  
 It should be considered that such heavy stimulation of the ovaries results in high 
levels of serum estrogen that can potentially fuel estrogen-sensitive tumors, worsening 
the malignancy (Chuai et al., 2012). For example, it has been estimated that 
approximately 60% of breast cancer patients have estrogen-sensitive tumors, so ovarian 
stimulation is often coupled with tamoxifen to act as a competitive inhibitor of oestrogen 
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(Noyes et al., 2010). Notably, there has been evidence of a correlation between ovarian 
stimulation and tumorogenesis that needs to be further explored before this treatment can 
be broadly offered. The risk suggests that many tumors, whether gonadal or extra-
gonadal, can be affected and even stimulated to grow by sex hormones such as 
gonadotrophins (Grynberg et al., 2012). Unfortunately, as with many new and promising 
technologies, the long-term data related to recurrence and prognosis cannot be used to 
determine the safety of such hormonal stimulation. 
 Even despite these notable caveats, delaying treatment for many fast-growing and 
aggressive cancers for weeks when they demand a quick response could ultimately be 
very detrimental to survivorship. Additionally, for most girls and young females, this 
delay in cancer treatment is unlikely to truly be considered an option by concerned 
parents who may have the final say in each case.  
 With embryo cryopreservation, there have been an encouraging number of 
successful re-implantations and pregnancies. Upon being thawed, as many as 90% of 
frozen embryos survived and were able to be implanted, with cumulative pregnancy rates 
reaching 30-40% success (Chuai et al., 2012).  
 
Oocyte Cryopreservation 
 Compared to embryo cryopreservation, oocyte cryopreservation is still considered 
to be in the early ages of research and testing. The idea behind oocyte cryopreservation is 
that the mature oocytes do not need to be fertilized first, but can be frozen as-is. This 
option does not limit individuals to either having sperm ready or using donor sperm and 
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confers some degree of reproductive autonomy. However, the negative considerations are 
much the same as embryo cryopreservation. The risks of delaying treatment during 
ovarian stimulation still hold true when freezing an oocyte, and as with any ovarian 
stimulation, this technique also increases the serum estrogen levels, causing potential 
hormonal imbalances and promoting estrogen dependent cancers. Oocyte 
cryopreservation also does not offer a solution for the younger, pre-pubescent population 
of cancer patients. 
 Additionally, oocyte cryopreservation is not completed as successfully due to the 
sensitive nature of unfertilized oocytes (Chuai et al., 2012). Researchers have found that 
these cells become damaged more easily and more frequently than their fertilized 
counterparts. Structurally, the oocyte is a large cell with high water and lipid content, and 
spindles that are sensitive to changes in temperature, making it much less stable during 
cryopreservation. Overall, the pregnancy rate with oocyte cryopreservation is about 2%, 
which is significantly lower when compared to the standard of embryo cryopreservation 
(Chuai et al., 2012). Though low, this statistic is quickly growing thanks to continued 
research in procedural techniques and basic sensitivities of the oocyte; encouragingly, 
live births have been reported using this method of fertility preservation. 
 In order to improve the success rate, techniques in cryopreservation need to be 
further developed. One current setback is the limited availability of human, immature or 
mature, oocytes for research. Methods that show potential in improving success rates are 
techniques such as vitrification (ultra-rapid freezing) and slow-freezing, and even trying 
to collect immature oocytes (Herraiz 2012). Evidence suggests that immature oocytes 
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could be quite successfully cryopreserved given their smaller cell size and lack of 
temperature-sensitive spindles. The difficulty with freezing immature oocytes arises with 
lower success rates promoting maturation in vitro (Chuai et al., 2012). Research at any of 
these problematic points could result in discoveries that would truly progress the field.   
 
Ovarian Tissue Cryopreservation 
 Ovarian tissue cryopreservation can be considered the most up-and-coming and 
promising technique and will receive significant attention here. Ovarian tissue 
cryopreservation is the only experimental option on the list that is suitable for pre-
pubescent females. With freezing of the tissue only, and without having to wait for proper 
ovarian stimulation, there is no delay in cancer treatment time. This property also makes 
is an attractive option for women with aggressive cancers who may not be able to afford 
to wait. Preservation of ovarian tissue could simply mean freezing a small piece of 
cortical tissue via biopsy or it could mean preservation of the entire ovary that is later 
dissected into fragments (Gracia et al., 2012). Though this method does not require delay 
and hormone stimulation, it does assume two additional surgical invasions: harvesting the 
tissue for preservation and later for retransplantation (Noyes et al., 2010). Amazingly, 
however, there have been reports of a handful of successful live births after re-
implantation of thawed ovarian tissue, both with assistance and spontaneous pregnancies. 
 In a study by Silber and Barbey (2010), transplantation of thawed ovarian tissue 
resulted in pregnancies and displayed drops of FSH levels that were comparable to fresh 
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tissue transplantation (Figure 12). Two of the patients shown in this figure ultimately 
resulted in a live birth. 
 Similarly to the other cryopreservation options, the quantity of human donor 
ovarian tissue to study is limited for research. Structurally, ovarian tissue and the 
primordial follicles it contains can be sustained through the freeze-thaw cycles of 
preservation and transplantation. Depending on factors such as the thickness of the 
sample, speed of the freeze-thaw cycles, and choice of cryoprotectant, the success and 
efficiency of the process can vary drastically (Herraiz, 2012). In addition to technical 
limitations of this process, other main limitations of ovarian tissue cryopreservation are 
the successful revascularization of the tissue post-cancer treatment and danger for 
reintroduction of cancer cells, potentially increasing the incidence of relapse. Recent 
mouse-models of thawed, xenografted ovarian cortex resulted in 4/18 mice relapsing and 
growing tumors. Due to this uncertainty, the current advice is that patients with 
Figure 12: FSH levels in 3 patients after retransplantation of ovarian tissue (Silber and 
Barbey, 2010). 
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leukemias, ovarian metastases, and other ovarian related tumors should not use this 
technique, as it is not safe (Gracia et al., 2012). And unfortunately, under current 
experimentation, many of the primordial follicles will be lost after transplantation due to 
reperfusion injury and ischemic damage from natural healing processes (Chuai et al., 
2012).  Figure 13 illustrates the extent of follicular loss after cancer treatments.  
One study at the University of Pennsylvania and the Children’s Hospital of 
Pennsylvania aimed to follow 21 cases of ovarian tissue preservations in individuals with 
various cancer types, ages 8-36. Though many of their personal characteristics, statuses, 
and treatment plans varied greatly, each patient required multidisciplinary attention from 
a pediatric oncologist, reproductive endocrinologist, pediatric surgeon, pediatric and adult 
clinical/research nurse, and a psychosocial counselor, a unique element of this study. The 
study raised many new questions for the field of oncofertility, such as what should the 
target age range be for this technology? How much ovarian tissue is optimal for freezing 
Figure 13. A) Absence of follicles in a patient being considered for ovarian tissue 
cryopreservation and transplantation vs. B) Fertile sister (Silber and Barbey, 2012) 
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and subsequent re-implantation? And though it is assumed to be an option for pre-
pubertal females, how effective is it actually? A finding of this study speaks to the need 
for a multidisciplinary aspect to this field. With a great deal of coordination required for a 
successful tissue harvesting and processing, followed by specific cancer treatment, and 
post-treatment care, oncofertility calls for a higher level of communication between 
caretakers (Gracia et al., 2012).  
 As mentioned earlier, options in cryopreservation include vitrification and slow-
freezing; varying these times have some unpredictable effects on cryopreservation and 
seem to be one of the fundamental research questions that must be answered before this 
technology can change the field of oncofertility. Much of the research that has been done 
is inconclusive and contradictory due to the variable nature of the work and seemingly 
endless combinations of cells, times, and solutions to test.  
 Another study aimed to compare ultra-rapid and slow-freezing techniques using 
various combinations of cryoprotectant solutions. They found that within the 
combinations they tried, ultra-rapid vitrification with Ethylene Glycol (EG) and Dimethyl 
sulphoxide (DMSO) as cryoprotectants was the safest procedure that best mimicked 
fresh, natural tissue in follicular density, proliferation, viability, and cell death (Herraiz 
2012). More studies such as this one could promote a whole new set of guidelines that are 
more specific, provide more options, and tailored to the range of individuals undergoing 
treatment.  
 
Trachelectomy 
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 Trachelectomy is a surgical technique for removal of the cervix. As an accepted 
surgical method for treatment of cervical cancers, trachelectomies are a part of the ASCO 
standard guidelines. The current trend of surgical techniques for lower stage cancers is to 
be conservative and acknowledge the importance of preserving fertility (Chuai et al., 
2012). Because cervical cancer is abundantly common in women under the age of 40, 
preservation of fertility is an important factor in treatment of this cancer. Indications for a 
trachelectomy in cervical cancer cases include still being in stage Ia1 (with lymph 
vascular space involvement), Ia2, or Ib1, having a lesion smaller than or equal to 2 cm, 
no upper canal involvement, no metastasis to the lymph node, and being a histologically 
squamous, adeno- or adenosquamous carcinoma (Lee et al., 2010). Comparative studies 
have shown recurrence rates comparable to full hysterectomies, indicating that 
trachelectomies are a successful method of keeping cervical cancer at bay. This view is 
not currently accepted by all because there are a limited sample of studies and trials that 
have been done (Chuai et al., 2012). As the medical community is driven by evidence-
based approaches, before conservative surgical techniques can be fully accepted and 
embraced, more convincing research needs to be done on both sides of the debate.  
 
Ovarian Suppression 
 There is some evidence that pre-pubescent girls are more protected against 
chemotherapy and radiation therapy, or perhaps are able to rebound more quickly than 
older women. Ovarian suppression is a controversial management method that is still not 
well understood and no exact mechanism has been suggested (Dillon, 2012). In theory, 
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suppression with a gonadotropin-releasing hormone (GnRH) analogue allows the ovary 
to mimic a pre-pubertal state while immersed in a more tolerable endocrine state similar 
to that of a pre-pubertal female (Chuai et al., 2012). Some evidence suggests that pre-
pubertal female survivors are more likely to continue on to have regular cycles of 
menstruation, and post-pubertal patients given GnRH-a are more likely to resume their 
cycles (Dillon, 2012). The research on this topic is polarizing; one meta-analysis of the 
current data concludes that there is a slight benefit to ovarian suppression, while others 
disagree (Chuai et al., 2012). The inconclusive nature of ovarian suppression prevents it 
from making ASCO’s list of fertility options. Though, if efficient, GnRH agonists would 
be an easy, cost-effective, and accessible method of preventing gonadotoxicity. For these 
reasons, further randomized trials with longitudinal follow-up in ovarian suppression 
seem worthwhile.  
 
Hormone Replacement Therapy 
 Hormone replacement therapy is not an option for everyone and must be 
considered a supplemental option post-treatment. In post-pubertal females, hormone 
replacement generally comes into play only after other methods have succeeded in 
preserving ovarian reserve and function. In these cases, its purpose is to aid fertility 
impaired by hormonal imbalances due to cancer treatments, for example, cranial 
irradiation resulting in hypogonadism through the hypothalamus-pituitary axis (Levine, 
2012). However, for pre-pubertal females, hormone replacement therapy can be used 
when sexual development and puberty is stunted post-treatment to promote normal 
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growth. Finally, this option is useful for women where premature ovarian failure has 
already occurred. For these women, loss of ovarian function is associated with onset of 
menopausal symptoms, an increased risk of cardiovascular health issues and loss of bone 
mineral density leading to osteoporosis (Dillon, 2012). Hormone replacement therapy in 
these individuals can be beneficial in alleviating these symptoms. 
 
Ovarian Tissue Culture in vitro 
 Though current methods of cryopreserving tissue are still being established, in 
vitro tissue engineering is being developed simultaneously. Tissue engineering will play 
an integral role in cryopreservation methods as researchers determine how to prolong the 
longevity of frozen tissue, the necessary growth factors needed to maintain proliferative 
tissue, and even methods of reviving arrested tissue. The most challenging aspect of 
tissue engineering is mimicking the local environment that supports follicle development 
within the ovaries. Any number of endocrine signals, paracrine pathways, and 
extracellular matrix environmental factors could be involved in oocyte production, 
making in vitro much about trial and error. It has been shown that growth of secondary 
follicles is easier, likely due to their stability, and just as effective for cancer patients.  
  
Male Fertility Preservation  
 Male fertility is certainly an important issue as well, but unlike female oocytes, 
sperm production is much more likely to recover and progress normally following cancer 
treatments; though, it should be noted that this recovery could take anywhere from 1 to 5 
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years. The recovery of spermatogenesis depends on cumulative dose of chemotherapeutic 
or radiation given and which class of drugs or treatment combination is given. When 
compared to effects on female fertility, it seems that cancer treatments like chemotherapy 
and radiation are just as damaging to the pre-pubescent male, with no protective 
endocrine effects noted (Dohle, 2010). During the whirlwind of a cancer diagnosis and 
pressure to treat the acute medical issue, male fertility options are seldom discussed. The 
ease and speed with which male fertility can be preserved without disrupting a treatment 
plan should be considered in each case. Sperm production begins at puberty, around age 
12, and sperm can be collected fairly easily (Dillon, 2012). However, in pre-pubertal 
males, the methods for preserving fertility are still largely experimental.  
 
Sperm Cryopreservation 
 Much like embryo cryopreservation, sperm cryopreservation is similarly a 
practiced and successful option for men. Sperm can be collected without any delay in 
cancer treatment by masturbation, electrostimulation, or testicular aspiration depending 
on the age, personal preference, and sperm counts. Reproductive success has been 
reported from thawed sperm with both insemination and in vitro fertilization, even with 
very low numbers of sperm (Dillon, 2012). With testicular cancers, however, much of the 
viable sperm is already lost or affected before a treatment regimen even begins. Studies 
have shown that as many as 12% of testicular cancer patients have no functional sperm to 
preserve. Cryopreservation of sperm does cause a decline in quality, i.e. motility and 
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morphology, but freeze-thaw cycles are less damaging to sperm than their oocyte 
counterparts (Dohle, 2010).   
 
Testicular Tissue Crypopreservation 
 Unfortunately, for pre-pubescent males, the options are severely limited. Current 
research is still in a young and theoretical stage. One option in currently in development 
explores the idea of extracting testicular stem cells and using in vitro maturation. Even 
assuming harvesting testicular tissue for spermatogonial stem cells is feasible, the 
majority of childhood cancers risk contaminating testicular tissue. It has been suggested 
that it only takes a reintroduction of 5 leukemia cells to cause a relapse (Dohle, 2010). 
Thus, an extremely sensitive method of selecting the cells to re-implant post-treatment 
must be developed to reduce the likelihood of reintroducing the cancer cells with it.  
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DISCUSSION 
 
Reproductive Outcomes in Longitudinal Studies 
 A number of challenges prevent methods of restoring fertility from being greatly 
successful. Transplantation of stored tissue must be perfected in a few key ways: 
determining the best positioning of re-grafted tissue for optimal function, proper 
revacularization and re-innervation, and influence of regional hormonal regulation (Smitz 
et al., 2009). It has been estimated that only about 20% of re-implanted tissue results in a 
successful live birth.  
 As described, the effects of cancer treatments do not only affect the reproductive 
system. Other factors can determine whether or not a pregnancy is carried to term and is 
successful. One example is that the use of anthracyclines such as doxorubicin can result 
in various degrees of cardiomyopathy. Additionally, irradiation of cardiac tissue can lead 
to damage and be dangerous for the mother in carrying a pregnancy to full-term. These 
conditions often make it difficult for a woman to even carry a pregnancy physiologically; 
with a dramatic increase in blood volume during gestation, a woman with extensive 
cardiovascular damage could be unable to support it without risk to her life. 
 Theoretically, men undergoing chemotherapy or radiation treatments who go on 
to bear children through normal methods might be at risk of producing offspring with 
congenital malformations. It is reasonable to think that chemotherapies with alkylating 
agents or intercalating agents could disrupt germ cell growth and introduce mutations that 
could be propagated. But so far, no evidence has shown this idea to be true; spontaneous 
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pregnancies to male cancer survivors have not proven to have more birth defects than a 
non-cancer specific population. Longitudinal follow-up in post-cancer treatment 
pregnancies must be a priority.  
 There have been a few notable large-scale studies, one of which is known as the 
Childhood Cancer Survivor Study (CCSS), an observational, longitudinal, retrospective 
cohort study. This study was developed in 1994 and funded by the NIH to learn more 
about the long-term effects of childhood cancer. Green et al., (2009) looked at a number 
of reproductive outcomes, like ovarian failure, pregnancy outcomes, and offspring health. 
They found that aside from the previous discussed problem of premature ovarian failure, 
other prevalent findings were those of premature labor and low-birth weight offspring to 
those individuals who had undergone cancer therapies.  
 Specifically, female survivors who received >25 Gy of abdominal-pelvic 
irradiation, resulted in 
offspring who were more 
likely to be underweight 
than those receiving a 
dose less than that. In 
Figure 14, a side-by-side 
comparison of females 
receiving abdominal-
pelvic irradiation vs. none 
shows a skew towards 
Figure 14: Comparing the distribution of birth weight by percentage 
between a-p or no a-p irradiation (Green, Sklar et al. 2009) 
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lower birth weights. Though the mechanism is still unclear, it has been suggested that a 
high-dose of radiation damages the uterine lining and vasculature, resulting in a less 
supportive environment. Additionally, there is a higher risk of miscarriage with 
abdominal-pelvic irradiation (Green, Sklar et al., 2009). In another set of data analysis of 
the CCSS, significant risk factors for not having a pregnancy included cranial irradiation 
of >30 Gy affecting the hypothalamus-pituitary functioning and abdominal/pelvic 
irradiation of >5 Gy, and did show dose-dependency (Green and Kawashima et al., 
2009). Overall, it seems that female survivors produce significantly less offspring as 
compared with their general population counterparts, for reasons that are still 
indiscernible.  
 In male survivors, only individuals who were treated with non-alkylating agents 
during chemotherapy showed an increased risk of producing underweight offspring 
(Green, Sklar et al., 2009). Those treated with higher doses of alkylating agents or who 
had a total cumulative dose of radiation >7.5 Gy were shown to be about half as likely as 
their sibling counterparts to father offspring. Interestingly, the male survivors who were 
analyzed seemed to not have been affected by many treatments, alone or in combination; 
they were just as likely to father offspring if treated with lower dose exposures (Green 
and Kawashima et al., 2009). 
 
Importance of Early Referral/Roles of the Oncologist or Gynecologist or Fertility 
Specialist 
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 Many of the previously discussed options, referring mostly to the female patients, 
require immediate action and could potentially delay treatment. Ovarian stimulation can 
take up to two weeks and must begin during the first few days of menstruation to 
optimize its effects. Because of the time sensitive nature of both cancer therapies and 
fertility preserving methods, oncologists should be ready to discuss these options and 
provide referrals to fertility specialists and/or reproductive endocrinologists upon giving 
the diagnosis.  
 Studies have shown that most men preparing for cancer treatment understand that 
sperm banking is an option and have had a discussion with their oncologist about future 
fertility. However, with women of childbearing age, less than half of oncologists 
regularly make these types of referrals with even fewer approaching the subject with 
younger patients (Green, Sklar et al., 2009). Even in one small, questionnaire-based, self-
reported study, approximately one third of respondents and their friends and family 
brought up the topic of fertility treatments with their physician rather than the other way 
around (Yee et al., 2012).  
 The best course of action would be to open up a dialogue that follows a 
comprehensive set of realistic options tailored to each individual case, focusing on 
overall wellness and medical ethics. Ideally, fertility discussions would regularly be a 
part of the treatment plan for each individual. There is a lack of evidence, currently, that 
explores the possible effects of fertility treatments on the cancer treatment success; 
though if there is little to no substantial delay in cancer treatment, effects can be expected 
to be minimal.  
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 Regardless of whether or not there is follow-through with actual fertility 
treatments, the most important aspect post-treatment is the patients’ quality of life. A 
retrospective study of about 1000 survivors, all of reproductive ages 18-40 at the time of 
diagnosis, were asked about their access to fertility information and subsequent feelings 
of life satisfaction. Slightly above previously reported numbers, just over half (61%) of 
the survivors received counseling and advice from an oncologist and/or fertility specialist 
on reproductive issues before their treatments. Interestingly, individuals who discussed 
potential infertility with a fertility specialist in addition to their oncologist displayed 
statistically significant lower levels of regret and greater overall quality of life than not 
only those who were unexposed to this information, but also those who had only talked to 
an oncologist. Not surprisingly, though only 4% of the interviewed women actually took 
action to preserve their fertility, the benefit shown by lower regret scores and higher 
quality of life was still statistically significant as compared to those who had only 
discussed fertility options but did not act on them (Letourneau et al., 2012).  
 Not only limited to personal well-being and quality of life for these individuals, 
open discussion about fertility options has been shown to have a positive effect on 
patients’ perceptions of their doctors, increasing trust and mental health (Chuai et al., 
2012). While the role of mental health on survivorship is unclear, there is a whole other 
field of psychiatric oncology studying the numerous mental comorbidities that 
accompany this disease (Chaturvedi, 2012). Whether or not a positive outlook and mental 
status truly has an effect on survivorship, presenting fertility options for the future 
suggests a life after cancer.  
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Ethical Considerations 
 As with any new technique on an already vulnerable population, there are a range 
of concerns and questions that arise. Religious and cultural beliefs regarding reproduction 
are certainly variable and should be considered personally for each individual case, but 
will only be acknowledged and not discussed here. In this dialogue, topics such as short- 
and long-term safety of the options, implications for offspring, harvest, use, and disposal 
of the tissue, and policy issues regarding access to treatment will be discussed.  
 One of the main questions that has already been touched upon is the ultimate 
effect of one treatment vs. another. As an oncologist, presenting the option of fertility 
preserving treatments may delay treatment of the cancer, however, not allowing the 
patient to make their own decisions of care when techniques are available infringes on 
their autonomy. Often these patients have a number of difficult decisions to make in a 
short amount of time and with many techniques still in experimental phases, the 
information presented to them must be clear, concise, and timely. It has already been 
suggested that only 5 cancerous cells in a preserved tissue could result in a reintroduction 
of the cancer (Dohle, 2010). This begs the question of whether these techniques are even 
safe enough to practice on individuals wishing to preserve their fertility yet.  
 Another major ethical concern is the suggestion of a fertility preservation plan 
that may ultimately pose a risk to future children. It has been mentioned that there might 
be a shorter expected lifespan of cancer survivors due to recurrence and comorbidities. 
The argument is that this may unfairly leave a future child with only one parent. While 
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worth mentioning, the general response and stance of the Ethics Committee of the 
American Society for Reproductive Medicine to this concern is that it is not a sufficient 
reason to deny patients access to the technology and oncologists should allow them to 
make the best decision for themselves (Chuai et al., 2012). When it comes to future 
offspring, though large scale studies such as the CCSS have thus far shown no increased 
risk of genetic defects, or risk to non-hereditary cancers, and/or other diseases, the 
concern remains. There has not been enough evidence and data to support the initial 
trends, and until that randomized, controlled research has been done, physicians should 
be cognizant of the possibility.  
 Furthermore, fertility preservation options are being developed that would allow 
pre-pubescent females to freeze tissue for long-term future use. The main ethical 
dilemmas that arise with these especially young minors have to do with consent. Only in 
children who are able to understand the implications and whose parents give their consent 
can these procedures be done (Chuai et al., 2012). Questions that introduce a degree of 
uncertainty into these decisions include: How young is too young? Who determines true 
comprehension of the minor? Are the costs and benefits overall more favorable to the 
quality of life of the child? Legally, and to avoid exploitation, when a minor’s tissue is 
preserved, it cannot be used until the minor can legally be responsible for it, when they 
turn 18 years old.  
 Because these cells are taken from vulnerable groups of people, i.e. cancer 
patients and potentially minors, extra steps need to be taken to ensure that these people 
are protected (Rodriguez, 2012). While human ovarian tissue is in high demand in basic 
  
 
 
 
 
47 
 
research and more patients are required for adequate statistical power in clinical studies 
in order to determine significant effects of certain treatments, using minors as test 
subjects becomes a gray area. Protecting the rights and advocating for vulnerable 
populations will remain in the forefront of oncofertility (Gracia et al., 2012).  
 There is no question that frozen oocyte/ovarian/testicular tissue belongs to the 
individual from which they were taken. However, if an embryo is preserved, the 
ownership could belong to both or either parent (Chuai et al., 2012). US law dictates that 
an embryo is considered property of both donors, but similar cases have ended differently 
in court (Rodriguez, 2012). The ethical and legal concerns that arise must be clearly 
addressed and agreed upon before the preservation occurs. Though it can be agreed that 
an embryo should not be used for reproductive purposes unless both parties agree, this 
concept becomes hazy in the event of divorce and donor sperm.  
 Even more complicated is the question of what happens in the event of death. It is 
not unreasonable to prepare for the fact that cancer patients undergoing treatments often 
do not survive. In these cases, a predetermined fate for the frozen tissues must be decided 
upon. One option is that the tissue and/or embryo is simply discarded; another proposes 
that it is donated to research (Dolin, 2010). More complicated is the use of the cells by 
the surviving partner. Current law dictates that in order for a surviving partner to use a 
frozen embryo, there must be written consent given by the deceased (Chuai et al., 2012). 
To make things even more complex, disposal of gonadal tissue and disposal of embryos 
is handled differently. It is unclear if gonadal tissue should be considered organs or 
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gametes, resulting in confusion about disposal and allows for potential allocation to the 
United Network of Organ Sharing (Rodriguez, 2012).  
 Finally, there is the question of who should pay for these options. Some believe 
that insurance companies should be required to pay for oncofertility options as they 
already pay for conditions arising from treatment, for example, breast reconstruction after 
a mastectomy. Others suggest that fertility treatments are an elective procedure that is 
still largely experimental and not medically necessary (Campo-Englestein, 2010). To pay 
for these options would also require that money is simply shifted and taken out of 
funding other conditions and diseases. Unfortunately, if fertility treatments are not 
covered, they become accessible mainly to educated, upper-class patients, when the 
demographics needing cancer treatment do not abide by these financial and societal lines. 
The resulting effect is limiting options for already vulnerable and disadvantaged groups 
(Rodriguez, 2012). 
 Ultimately the ethical considerations surrounding oncofertility treatments should 
be tailored to a person-to-person basis. In practice, there are roadblocks allowing this to 
occur. The ethical and legal implications on an individual level can be discussed and 
considered between the patient, oncologist, and reproductive specialist. Since the field of 
oncofertility has received more widespread recognition, special cases have raised 
questions and demanded defined lines when uncertainty arises (Camp-Englestein, 2010). 
Moreover, the broader social considerations need to be further discussed so that 
oncofertility treatment options are ethically and financially accessible to all.  
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CONCLUSIONS 
 Many considerations must come into play before cancer therapy begins, but future 
reproductive concerns have only recently been introduced into the conversation. 
Advances in diagnostics and therapeutics are made almost every day, leaving the burden 
of cancer on an ever-growing population. Though slowly improving, the focus of 
oncologists has been on treating and/or curing the malignancies without much discussion 
as to the damage it may deliver to reproductive capabilities.  
 The young field of oncofertility gives patients and physicians hope that there is a 
future after cancer and can greatly improve the subsequent quality of life for these 
individuals. Certainly, there are notable gaps in knowledge at all levels of research, but 
strides are made each day to bridge these holes. Longitudinal studies are an important 
way to track and observe long-term effects of certain treatment combinations. But, as 
cancer therapeutics are constantly being developed and changed, the data from each new 
cohort of survivors will tell a different story.  
Patients of childbearing age and younger make up a diverse population in terms of 
factors such as physical attributes and age, and also with respect to other demographic 
differences such as race and basic lifestyle. In light of this diversity, the treating 
physician must consider options that make sense for an individual’s cancer type, 
progression, age, other associated comorbidities, and future wishes. Cooperation between 
medical disciplines, such as oncology, surgery, reproductive medicine, endocrinology, 
and psychiatry will bring about a new era of interdisciplinary care. Cooperation between 
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fields, like bioethics, law, and medicine will continue and contribute to the conversation 
about social divisions.  
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